Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America.

Ef fi cacy of a tetravalent dengue vaccine in children in Latin America. Engl J 2015; 372:113 Dengue is a mosquito-borne disease caused by 1 of 4 virus serotypes from the fl avivirus genus present in tropical and subtropical regions. This study reports the results from a phase 3 randomized, blinded, placebo-controlled ef fi cacy trial of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) involving healthy children ages 9 to 16 years in 5 Latin American countries. The study, sponsored by Sano fi Pasteur, took place in 22 centers in Colombia, Brazil, Mexico, Puerto Rico, and Honduras from June 2011 to March 2012. The investiga-tional vaccine consists of 4 recombinant dengue vaccine vi-ruses, which were constructed by replacing the genes that encode the premembrane and envelope proteins of the yel-low fever 17D vaccine virus with those from wild-type dengue viruses.